- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
Source: The post is based on the article “India’s first mRNA vaccine against Omicron approved” published in The Hindu on 21st June 2023
What is the News?
India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM has been approved under emergency use guidelines by the Drug Controller General of India.
What is GEMCOVAC-OM?
GEMCOVAC-OM is India’s first indigenous mRNA vaccine for the Omicron variant of the novel coronavirus.
Developed by: Pune-based Gennova Biopharmaceuticals Ltd
Eligibility: Those who are 18 years of age and older can take the vaccine as a booster dose. This can be administered safely to individuals who have received two doses of either Covaxin or Covishield.
Features: It is a thermo-stable vaccine, which does not require ultra-cold chain infrastructure used for other approved mRNA-based vaccines, making it easy for deployment pan India.
– It is delivered intra-dermally using a needle-free injection device system.
– When administered intradermally in participants as a booster, it generated significantly higher immune responses.
